San Diego-based biotech company aTyr Pharma announced today its first clinical trial in FSHD patients of its investigational new drug Resolaris™. The Phase 1b/2 study is a double-blind, placebo-controlled, multiple ascending dose trial in up to 44 FSHD patients at multiple sites in the European Union. The exploratory trial is designed to evaluate safety, tolerability, pharmacokinetics and… Read More »
aTyr Announces First FSHD Clinical Trial of Resolaris™
Meet Kyle Bennett, snowboarder
Kyle Bennett is a 23 year old college student in Sacramento, California, who has FSH muscular dystrophy. An outstanding baseball player when he was younger, he had to give that up. And then he discovered snowboarding. “I knew I’d found something that will change my life forever,” he says. His dream is to show younger kids with… Read More »
A recap of 2014 research highlights
Check out our press release “A Look Back: FSHD Research Advances in 2014,” which summarizes some important advances in our understanding of medical as well as fundamental scientific issues. These include new data on reduced lung capacity in FSHD patients, the first high-throughput drug screen for potential treatments, clues as to why muscles are targeted by… Read More »
Welcome to our new website!
We hope you like it. We have migrated and updated the valuable content from our previous website and added new features, such as a blog (like this post, always visible on the homepage), and a navigation system designed to make it easier for you to find the wealth of information on this site. Our new website is… Read More »
The Truth Hurts, but I Can Bear It
The following essay was written by Zabrisa, a 16 year old with FSHD who lives in Arizona. “Are you strong enough? Are you really sure you can do this, you’re not too weak?” “You’re such an inspiration for chasing your dreams.” “Smile, Zabrisa!” “You look so weird.” “Your ears–what are those things in your ears?”… Read More »